State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
|
|
- Clifford Owen
- 5 years ago
- Views:
Transcription
1 State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari
2 Disclosure Biosense Webster (J&J): Patent licensing agreement Ospedale F. Miulli Acquaviva delle Fonti - Bari
3 Randomized clinical trial Vs. Real life data
4 Rivaroxaban Dataset Highest quality Independent Central Adjudication Committee (CAC) RCT Prospective, noninterventional study Rocket AF 1 Xantus 2 Xapass 3 Prospective Registry Dresden NOAC Registry 4 US PMSS 5 Retrospective databases RELIEF 6 REVISIT US 7 1) Patel MR et al, N Engl J Med 2011;365: ) Camm AJ et al. Eur Heart J 2016;37: ) Abstract presented at ESC congress ) Hecker J et al, Thromb Haemost 2016;115: ) Tamayo S et al, Clin Cardiol 2015;38: ) Coleman CI et al. Int J Cardiol 2016;203: )Coleman CI et al, Curr Med Res Opin 2016;Sep 20:1-7
5 XANTUS: Study Objective and Design Objective: to collect real world data on NVAF patients treated with rivaroxaban Primary outcomes: major bleeding, all-cause mortality, any other adverse events Population: Adult patients with NVAF receiving rivaroxaban for stroke/non-cns SE prevention N=6,784 Rivaroxaban; treatment duration and dose at physician s discretion Data collection at initial visit/hospital discharge and quarterly* 1 year Prospective, single-arm, observational, non-interventional phase IV study Statistical analyses were descriptive and exploratory in nature Final visit: 1 year # *Exact referral dates for follow-up visits not defined (every 3 months recommended); # for rivaroxaban discontinuation 1 year, observation period ends 30 days after last dose. Observational design means no interference with clinical practice was allowed Camm AJ et al. Eur Heart J 2016;37:
6 Rivaroxaban: Randomized Clinical Trial and the Real World Rivaroxaban 1 XANTUS 1 Baseline ROCKET AF CHADS Rivaroxaban 2 41% 0 1 0% 41% 29% 30% 29% 19% 2 3 Heart failure 13% 63% 87% 13% 30% 75% 37% Hypertension Age >75 years 44% 91 % 87% 20% Diabetes 40% 19% Prior stroke # 55% 10% Prior MI 17% *Events per 100 patient-years; # includes prior stroke, SE or TIA Adapted from 1. Camm AJ et al. Eur Heart J 2016;37: Patel MR et al, N Engl J Med 2011;365: CHADS 2 score
7 Incidence rate Event per 100 patient-years and ROCKET AF XANTUS 4,0 3,6 CHADS 2 Prior stroke* 3,0 ROCKET AF % XANTUS % 2,0 1,7 2,1 1,9 1,9 1,7 2,0 1,0 0,8 0,7 0,5 0,4 0,9 0,0 Stroke/SE Major bleeding Death All strokes ICH GI bleeding *Includes prior stroke, SE or TIA. {1. Camm AJ et al, Eur Heart J 2015; doi: /eurheartj/ehv466}
8 Objective: XAPASS To confirm the safety and effectiveness profile of rivaroxaban across NVAF patients in Japanese realworld clinical practice. Primary outcomes: adverse events (AEs) including bleeding events (eg, major bleeding) and efficacy events (stroke, systemic embolism [SE], and myocardial infarction [MI]) Study population: patients with NVAF in Japan who start treatment with rivaroxaban for stroke/non-cns SE prevention Rivaroxaban; treatment duration and dose (15/10 mg) at the attending physician s discretion Data collection at visit, 6-month, 1-year, and 2-year Enrolment: from April 2012 to June years Standard observation period Once a year Maximum 5 years Follow-up investigation Prospective, single-arm, observational study Statistical analyses were descriptive and exploratory in nature Ogawa et al., J Stroke Cerebrovasc Dis, 2014;23:2520-6
9 XAPASS: Results Hori M. et al: Circ J 2012;76: Abstract presented at ESC congress 2016 Results are not intended for direct comparison XAPASS mean CHADS 2 score= 2,2 J-ROCKET AF mean CHADS 2 score=3.3
10 Rivaroxaban Provides a Consistent and Unique Dataset Covering the Full Patient-Risk Spectrum Highest quality Independent Central Adjudication Committee (CAC) RCT Prospective, non-interventional study Rocket AF 1 Xantus 2 Xapass 3 Prospective Registry Dresden NOAC Registry 4 US PMSS 5 Retrospective databases RELIEF 6 REVISIT US 7 1) Patel MR et al, N Engl J Med 2011;365: ) Camm AJ et al. Eur Heart J 2016;37: ) Abstract presented at ESC congress ) Hecker J et al, Thromb Haemost 2016;115: ) Tamayo S et al, Clin Cardiol 2015;38: ) Coleman CI et al. Int J Cardiol 2016;203: )Coleman CI et al, Curr Med Res Opin 2016;Sep 20:1-7
11 Dresden NOAC Registry Effectiveness and Safety of Rivaroxaban for AF Using data from the Dresden NOAC Registry, a large multicentric registry, we prospectively evaluated the management and outcome of patients with SPAF treated with rivaroxaban Major bleeding ROCKET AF (n=7111) (mean CHADS 2 =3,5) 1 Stroke/TIA/SE All rivaroxaban SPAF patients Dresden registry 2 (n=1204) (mean CHADS 2 =2,4) Patel MR et al, N Engl J Med 2011;365: Adapted from Hecker J et al, Thromb Haemost 2016;115: Results are not intended for direct comparison
12 % pts/year Outcome of VKA treated patients with AF not switched to NOACs-Dresden NOAC Registry Stroke TIA/SE MB Stroke TIA/SE MB VKA, median TTR 75.5% 1 Rivaroxaban 2 1. Adapted from Michalski et al, Thromb Haemost 2015;114: Adapted from Hecker J et al, Thromb Haemost 2016;115:939-49
13 Rivaroxaban Provides a Consistent and Unique Dataset Covering the Full Patient-Risk Spectrum Highest quality Independent Central Adjudication Committee (CAC) RCT Prospective, non-interventional study Rocket AF 1 Xantus 2 Xapass 3 Prospective Registry Dresden NOAC Registry 4 US PMSS 5 Retrospective databases RELIEF 6 REVISIT US 7 1) Patel MR et al, N Engl J Med 2011;365: ) Camm AJ et al. Eur Heart J 2016;37: ) Abstract presented at ESC congress ) Hecker J et al, Thromb Haemost 2016;115: ) Tamayo S et al, Clin Cardiol 2015;38: ) Coleman CI et al. Int J Cardiol 2016;203: )Coleman CI et al, Curr Med Res Opin 2016;Sep 20:1-7
14 Major Bleedig (MB) in patients with NVAF: pharmacovigilance of patients taking rivaroxaban Patients characteristics MB n=478 No MB n= Age, y, mean (SD) 78,4 (7,7) 75,7 (9,7) Comorbid condition, % 100,0 87,0 CHADS2 score, mean (SD) 3,0 (1,2) 2,2 (1,3) CHA2DS2-VASc score, mean (SD) 4,8 (1,5) 3,7 (1,7) MB characteristics* MB n=478 MB cases with fatal outcome 14 MB incidence rate %person-years (95% CI) 2,86 (2,61-3,13) Bleeding cases with fatal outcome (95% CI) 0,08 (0,05-0,14) Adapted from Tamayo S. et al, Clin Cardiol 2015;38:63-8 *MB classified using the Cunningham et al. defintion including: GI bleeding, hemorragic Strokes and other intracranial bleeds, genitourinarybleeding and bleeding at other sites.
15 Major bleeding events (%/year) Real World Evidence: Major Bleeding in Patients with Renal Disease Taking Rivaroxaban (US DoD) Analysis of electronic records from the DoD over a 2-year period Of 39,052 rivaroxaban users, 15.5% had renal disease Major bleeding in patients taking rivaroxaban ,52 Mean CHA 2 DS 2 - VASc 5.2 Renal disease 2,59 Mean CHA 2 DS 2 VASc 4.7 No renal disease Major bleeding rates were higher in patients with renal disease than those without, and CHA 2 DS 2 -VASc scores were also higher in patients with renal disease Error bars indicate 95% CI Tamayo et al, Circulation 2015;132: abstract A15905
16 Real World Evidence for Patients with Renal Impairment Major bleeding Fatal bleeding 4,49 4,70 4,52 0,28 0,74 0,09 Rivaroxaban Warfarin Rivaroxaban Rivaroxaban Warfarin Rivaroxaban %/year %/year %/year %/year %/year %/year ROCKET AF RENAL IMPAIRMENT TAMAYO RENAL IMPAIRMENT ROCKET AF RENAL IMPAIRMENT TAMAYO RENAL IMPAIRMENT 1. Adapted from Fox et al, Eur Heart J 2011;32: adapted from Tamayo Poster presentation at AHA 2015
17 Real World Evidence for Patients with Diabetes Mellitus Major bleeding 3,79 3,90 3,68 Intracranial hemorrhage 0,50 0,82 0,19 Rivaroxaban Warfarin Rivaroxaban Rivaroxaban Warfarin Rivaroxaban %/year %/year %/year %/year %/year %/year ROCKET AF DIABETES TAMAYO DIABETES ROCKET AF DIABETES TAMAYO DIABETES Adapted from: 1.Bansilal S et al, Am Heart J 2015;170: e8; 2.Patel M et al. Major bleeding among rivaroxaban users with non-valvular atrial fbrillation and diabetes. Poster presentation at the American College of Cardiology 65th Annual Scientifc Session. Chicago, Illinois, 2016
18 %/year The RELIEF Study Demonstrated Favourable Effectiveness of Rivaroxaban in NVAF Patients in Real-World Practice RELIEF: retrospective study of German outpatients newly initiated on rivaroxaban or VKA using data from an electronic medical record database VKA (n=1039) Rivaroxaban (n=1039) *Not otherwise specified Composite endpoint Coleman C et al, Int J Card Med 2015;203: Ischaemic stroke TIA ICH Other nontraumatic MI ICH 0.6
19 REVISIT-US Study Design to Optimize Internal Validity Combined Endpoint of Ischemic Stroke and ICH Most likely to be coded accurately and with less variability in claims data and of equal importance to allow for benefit/risk assessment Used validated ICD-9 coding algorithms and restricted codes to the primary diagnosis code position May miss cases, but greater robustness in those identified Coleman CI et al. Curr Med Res Opin 2016;20:1-7
20 REVISIT-US Baseline characteristics Parameters Rivaroxaban (n=11,411) VKA (n=11,411) Apixaban (n=4083) VKA (n=4083) Age, years, mean (DS) 70.7 (11.0) 70.7 (11.4) 71.2 (11.3) 71.0 (11.3) Gender, % (n) male 53.6 (6115) 53.9 (6145) 53.2 (2217) 53.6 (2189) CHADS 2 score, mean (DS) CHA 2 DS 2 -VASc score, mean (DS) HAS-BLED score, mean (DS) 1.92 (1.08) 1.94 (1.08) 1.93 (1.07) 1.92 (1.07) 3.46 (1.37) 3.48 (1.35) 3.47 (1.38) 3.47 (1.35) 1.62 (0.69) 1.62 (0.71) 1.66 (0.72) 1.65 (0.69) NAOC low dose 15 mg od; 17.3% N/A 2.5 mg bid; 15.5% N/A Modifed from: Coleman Cl et al,curr Med Res Opin 2016 Sep 15 Coleman CI et al, presented at ESC 2016
21 REVISIT US - Significant Reduction in the Combined Endpoint for Rivaroxaban vs warfarin Rivaroxaban was associated vs warfarin with a Significant 47% reduction in ICH Non-significant 29% decrease in ischemic stroke Significant 39% reduction in the combined endpoint of ICH and ischemic stroke Rivaroxaban Warfarin Rate (%/year) Rate (%/year) HR (95% CI) rivaroxaban vs. warfarin HR (95% CI) rivaroxaban vs. warfarin ICH ( )* Ischemic stroke ( ) Combined ( )* *p<0.05 0,125 0,25 0, Favors rivaroxaban Favors warfarin Coleman CI et al. Curr Med Res Opin 2016;20:1-7
22 HR vs Warfarin HR vs Warfarin ICHs and Ischaemic Strokes of NOACs Compared with VKA in Large Retrospective Observational Analysis 1 0,8 0,6 0,4 0,2 0 1,4 1,2 1 0,8 0,6 0,4 0,2 0 ICH 0,71 0,71 0,66 0,53 0,53 0,56 0,38 0,37 0,3 Coleman CMRO 2016 Staerk EHJ 2016 Larsen BMJ 2016 Rivaroxaban Dabigatran Apixaban Ischaemic Stroke 1,22 1,13 1,11 0,98 0,87 0,89 0,89 0,71 0,82 Coleman CMRO 2016 Staerk EHJ 2016 Larsen BMJ 2016 Rivaroxaban Dabigatran Apixaban Warfarin Warfarin Adapted from Coleman CI et al. Curr Med Res Opin 2016;20:1-7; Staerk L. et al. Eur Heart J 2016.pii:ehw496.[Epub ahead of print]; Larsen TB et al. BMJ 2016;353:i3189 Results are not intended for direct comparison
23 Safety Profile of Rivaroxaban Confirmed Through Real-World Evidence Regardless of Data Source 6 Major bleeding event rate/year Randomized Prospective clinical trial registry ROCKET AF 1* Dresden NOAC 2# n=7111 n= % 3.1% 2.9% Retrospective Observational database study US DoD PMSS 3 XANTUS 4* n=27,467 n= % Major GI bleeding 2.0% event rate/year 1.2% 1.5% 0.9% Mean CHADS 2 score ** 3,0*** 2.0 ** *** Referred to patient population with no major bleeding cohort ( representative of > 98% of the patient population) Referred to pts with major bleeding ( Beyer-Westendorf et Al. Thromb and Haemost Suppl 2/2016) *Major bleeding definition according to ISTH; # modified ISTH definition (additionally included surgical revision from bleeding); major bleeding defined by the Cunningham algorithm 5 ; Warfarin MB 3,4% Warfarin MB-GI 1,24 1. Patel MR et al, N Engl J Med 2011;365: ; 2. Hecker J et al, Thromb Haemost 2016 Jan 21;115(5) ]; 3. Tamayo S et al, Clin Cardiol 2015;38:63 68; 4 ; Camm AJ et al, Eur Heart J 2016;37(4): Cunningham A et al, Pharmacoepidemiol Drug Saf 2011;20: Modified from Beyer-Westendorf J et al Thromb Hemost 2016:116:S13-S23 Results are not intended for direct comparison
24 Adherence and Persistence Start medication or observation Adherence Percentage of doses taken as prescribed Persistence Days taking medication (without exceeding permissible gap) Stop medication or end observation Cramer JA et al. Value Health 2008;11(1):44-47
25 Non optimal adherence (PDC <80%) and ischemic stroke M.J. Alberts et al. / International Journal of Cardiology 215 (2016) 11 13
26 Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States Retrospective cohort analysis of the US MarketScan Coleman, et al., PLOS ONE DOI: /journal.pone
27 Comparison of Adherence to Rivaroxaban vs. Apixaban Among Patients with AF Objective: to compare adherence with rivaroxaban and apixaban among patients with NVAF in routine clinical practice. Proportion of days covered (PDC) 0.80-matched analysis of apixaban and rivaroxaban users (n=2992 per cohort) Proportion of days covered (PDC) 0.90-matched analysis of apixaban and rivaroxaban users (n=2992 per cohort) Percentage Point Difference: 5,4; p < ,3% 79,9% Percentage Point Difference: 3,6; p = ,8% 72,2% Percentage Point Difference: 8,1; p < Percentage Point Difference: 78,8% 7,0; p < ,7% 61,9% 54,9% PDC at 90 days PDC at 180 days PDC at 90 days PDC at 180 days PDC: number of days of supply divided by 90 and 180 days respectively. McHorney CA et al. Clin Ther 2016;doi: /j.clinthera [Epub ahead of print] Rivaroxaban Apixaban
28 Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications rivaroxaban: n = 4194, dabigatran: n = 5489, apixaban: n = 265 McHorney CA, Crivera C, et al. Curr Med Res Opin Sep 22:1-16
29 Adjusted HR (65%CI) for ischemic stroke when PDC* < 80% Association between OD and BID DOAC adherence in NVAF patients and rates of ischemic stroke 1,5 1 0, % All DOAC users +47 % Oncedaily users +50 % Twicedaily users Suboptimal adherence to DOACs was found to be associated with an increased hazard of ischemic stroke Patients prescribed DOACs requiring twice-daily dosing were less adherent than once-daily users. These results did not support the hypothesis that twice-daily dosing of a DOAC is more forgiving in the presence of suboptimal adherence Adapted from Alberts MJ et al, Int J Cardiol 2016;215:11-3 CI= confidence interval; HR= hazard ratio; N= sample size; DOAC= direct oral anticoagulant; PDC= proportion of days covered; Pys = person years. a PDC < 80% represents suboptimal adherence. b p < compared to once-daily DOAC use.
30 One-Third of Twice-Daily Prescribed Medications Were Being Taken Once Daily Therapy adherence Self-reported patient survey (N=266) Taking OAC once daily Taking OAC twice daily 94% Rivaroxaban 6% 27% 73% Dabigatran 30% Apixaban 70% 86% Warfarin 14% Andrade JG et al, Can J Cardiol 2016;32:747-53
31 Conclusions Real world data confirm the safety and effectiveness profile of rivaroxaban when compared to randomized clinical trial data The adherence and persistence are poor in warfarin users but are also not optimal in direct oral anticoagulants Adherence and persistence are higher in Rivaroxaban users when compared to warfarin and twice day direct oral anticoagulants users
Gli studi "real-world" che cosa aggiungono alla nostra conoscenza? Vittorio Pengo (Padova)
Gli studi "real-world" che cosa aggiungono alla nostra conoscenza? Vittorio Pengo (Padova) Dimensions of Real World Evidence Effectiveness and safety Adherence and persistence Management of the active
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationReal World Evidence on the Use of NOACs
Real World Evidence on the Use of NOACs Prof. Fausto J. Pinto, MD, PhD, FESC, FACC ESC President Head, Cardiology Dpt/University Hospital Sta Maria-HPV University of Lisbon, Portugal RIYHAD, 12 H FEBRUARY
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationΧάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationRivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice
Thrombosis and Haemostasis Supplement S13 Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice Jan Beyer-Westendorf 1 ; A. John Camm 2 ; Craig I. Coleman 3 ; CAPT Sally
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationNOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationNOAC in the Real World
NOAC in the Real World Francesco Dentali Dipartimento di Medicina e Chirurgia Università dell Insubria, Varese Conflitti di Interesse Letture Protocolli di Ricerca Advisory Boards Bayer BMS/Pfizer Boehringer
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationΕίναι τα δεδομένα από τον πραγματικό κόσμο σε συμφωνία με τα αποτελέσματα των τυχαιοποιημένων κλινικών δοκιμών?
Είναι τα δεδομένα από τον πραγματικό κόσμο σε συμφωνία με τα αποτελέσματα των τυχαιοποιημένων κλινικών δοκιμών? Δ. ΡΙΧΤΕΡ, MD, FESC, FAHA -Διευθυντής Καρδιολογικής Κλ. Ευρωκλινικής Αθηνών -Αντιπρόεδρος
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationAnti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone
Anti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone Doreen Tan Cardiology Specialist Pharmacist 2017.04.08 Navigation Map Atrial Fibrillation What s the fuss?
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationNew Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationNOAC: Future perspectives: academic perspective. Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands
NOAC: Future perspectives: academic perspective Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands To discuss Lessons from the NOAC-VKA studies and optimal VKA management
More informationΕπιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική;
2ο ΣΥΝΕΔΡΙΟ ΚΑΡΔΙΑΓΓΕΙΑΚΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΑΘΗΝΑ 2017 Επιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική; Κωνσταντίνος Π. Λέτσας, MD, FEHRA Β Καρδιολογική Κλινική
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationRelationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial
Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Jonathan P. Piccini, Frank Harrell, Yulia Lokhnygina,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationGregory Y. H. Lip 1,2 Xianying Pan 3 Shital Kamble 3 Hugh Kawabata 3 Jack Mardekian 4 Cristina Masseria 4 Amanda Bruno 3 Hemant Phatak 3.
Received: 16 May 2016 Accepted: 1 July 2016 DOI: 10.1111/ijcp.12863 ORIGINAL ARTICLE Major bleeding risk among non- valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationRivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion
Rivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion Riccardo Cappato Arrhythmia and Electrophysiology Research Center, IRCCS Humanitas Research
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationEffectiveness and Safety of Non Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
Effectiveness and Safety of Non Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation 3 2018 Stefan H. Hohnloser; Edin Basic; Christopher Hohmann;
More informationCurrent state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More informationModern Management in Primary Care (AF1)
Modern Management in Primary Care (AF1) Dr Ravi Assomull Consultant Cardiologist London North West Healthcare NHS Trust Dr Yassir Javaid Primary Care Cardiovascular Lead East Midlands Strategic Clinical
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationBoehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017
Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Dr André Peeters Service de Neurologie Cliniques Universitaires Saint-Luc / U.C.L. 1200 BRUXELLES Introduction 1. Aim NOACS
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationStroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More information